Siteng Chen, MD, Ph.D, comes from Shanghai Jiao Tong University School of Medicine.
Dr. Chen is a young researcher in the field of immunotherapy on urological cancer. He graduated with Science and Technology Innovation Scholarship in 2016 from Southern Medical University. During his graduate studies in Shanghai Jiao Tong University, his have published five excellent research papers in international journals focus on urologic oncology. He has illuminated induction BCG followed by maintenance BCG instillation after TUR, compared with induction BCG along, could reduce the risk ratios of tumor recurrence and tumor progression, and prolong recurrence-free survival (Int J Surg. 2018). He has also successful reported multi-omics perspective on the tumor microenvironment based on PD-L1 and CD8 T-Cell infiltration in urothelial cancer (J Cancer. 2019). He is now trying to translate his scientific research achievements into clinical application for patients with urological cancer.
Friday, May 15, 2020
7:00 AM – 9:00 AM